GlassScriptPhysician profile
Todd L Beyer
NPI 1407859275
$19,911.80
in general payments reported to CMS, 2019-2025
38 companies · $2,291 in 2025
The $2,291 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $285 · 2021: $157 · 2022: $767 · 2023: $14K · 2024: $1,785 · 2025: $2,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $10K · Food and Beverage: $6,627 · Travel and Lodging: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $10,387.50 |
| Food and Beverage | $6,627.02 |
| Travel and Lodging | $1,154.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $12,960.98 | 2020-2023 | Tepezza |
| Alcon Vision LLC | $1,759.54 | 2022-2025 | Clareon, Hydrus Microstent, Argos |
| Abbvie INC. | $667.43 | 2022-2025 | Xen Glaucoma Treatment System, Durysta |
| Rayner Intraocular Lenses Limited | $597.29 | 2023-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| New World Medical,INC. | $570.23 | 2022-2023 | |
| Amgen INC. | $510.81 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $399.34 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $327.40 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Dompe US, INC. | $267.49 | 2019-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $258.74 | 2019-2025 | Cequa |
| Ivantis, INC | $199.80 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $172.90 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $140.20 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $137.17 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $127.63 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Beyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.